The U.S. Department of Justice's move to approve German pharma company Bayer AG's acquisition of U.S.-based Monsanto Company (NYSE: MON) prompted at least one Wall Street analyst to turn bearish on the stock.
Argus' Bill Selesky downgraded Monsanto's stock rating from Buy to Sell.
The DOJ offered its seal of approval for Bayer's proposed acquisition of Monsanto, but before the deal can close, regulators from Canada and Mexico must sign off as well, Selesky said in the downgrade note. Nevertheless, both companies expect the deal to be completed by the end of the second quarter. (See the analyst's track record here.)
A downgrade of Monsanto's stock is warranted, as upside above the $128 price tag on the deal is unlikely, Selesky said. It should be noted the stock is trading at a discount to the $128 acquisition cost, as it closed at $125.40 on Friday.
Bayer's rationale for the acquisition was that it will increase its core EPS by a mid-single digit range in the first year after the deal closes, the analyst said. It should increase at a double-digit rate in the following years, he said. In addition, the deal is expected to generate synergies of $1.5 billion in the third year after closing.
Shares of Monsanto were trading down slightly at $125.39 at the time of publication Monday morning.
3 Market Winners From A Bipartisan Farm Bill In 2018
Monsanto Displays Robust Research & Development Moves
Latest Ratings for MON
|Apr 2018||BMO Capital||Downgrades||Outperform||Market Perform|
|Oct 2017||Wells Fargo||Maintains||Market Perform|
View More Analyst Ratings for MON
View the Latest Analyst Ratings
See more from Benzinga
- Stephens Downgrades McDonald's Ahead Of Q1 Report
- Benzinga Pro's 5 Stocks To Watch Today
- Analyst: Muted Expectations For IBM Heading Into Q1 Earnings
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.